SHI
RSLS

SV Health Investors’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

SV Health Investors’s Portfolio RSLS Stock Details RSLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,072
Closed -$3.26M – 9
2018
Q1 		$3.26M Buy
+1,072
New +$3.41M 2.45% 7

Other funds holding RSLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
RWP
RWA Wealth Partners Newton, Massachusetts $10.4B AUM 21.69% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SV Health Investors's RSLS Position: Q2 2018 in Review

SV Health Investors sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q2 2018, closing a stake of 1,072 shares — an estimated $3.26M sold.

SV Health Investors first reported a position in RSLS in Q1 2018 and held it in 1 quarter. The position peaked at $3.26M in Q1 2018. 11 funds tracked by Wall St. Rank hold RSLS as of Q2 2018.

  • SV Health Investors reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • SV Health Investors sold 1,072 ReShape Lifesciences Inc. Common Stock shares in Q2 2018, an estimated $3.26M.
  • SV Health Investors first reported a position in ReShape Lifesciences Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • SV Health Investors's ReShape Lifesciences Inc. Common Stock position peaked at $3.26M in Q1 2018.
  • 11 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q2 2018.

Based on SV Health Investors's 13F filing for Q2 2018, filed 6 Aug 2018.